Drug discovery state of the art automation technologies offered at G-INCPM

The Maurice and Vivienne Wohl Institute for Drug Discovery unit within the Grand-Israel National Center for Personalized Medicine (G-INCPM) serves Israeli researchers from universities, research institutes and biopharmaceutical companies, providing high throughput screening (HTS) in order to support biomedical discovery and therapeutic and prophylactic molecules.

HTS is a popular approach in drug discovery in which a relatively large number of chemical perturbants can be tested against a target or several targets.

HTS brings together expertise in liquid handling and robotic automation and multi-mode plate readers to perform automated biological reactions over a relatively short period of time. Benchtop assays are scaled down through miniaturization to 384-well or 1536-well formats for significant savings in reagent costs and dramatic increases in throughput.

This poster summarizes the state of the art equipment and technologies that our institute provides for serving researchers emphasizing their potential uses and applications.